Sequenom Inc.
SQNM
NASDAQ2.39
USD
- -
- -
CIK
0001076481
Return %
Stock
S&P500
1Y
- -
26.53
3Y
- -
76.60
5Y
- -
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- IPO Date
- Feb 1, 2000
- CIK
- 0001076481
- Similar Companies
- Business
- Sequenom Inc. (SQNM), a life sciences company headquartered in San Diego, California and founded in 1994, develops and commercializes molecular diagnostic testing services and genetic analysis solutions focused on women's health, reproductive genetics, and oncology; core offerings through its wholly owned subsidiary Sequenom Center for Molecular Medicine include the MaterniT21 PLUS noninvasive prenatal test for trisomy 21, 18, and 13, VisibiliT for personalized risk scoring of fetal chromosomal abnormalities, SensiGene RHD fetal genotyping, HerediT carrier screening for disorders such as spinal muscular atrophy and fragile X syndrome, RetnaGene for ophthalmological conditions, and NextView microarray analysis of fetal samples obtained via amniocentesis or chorionic villus sampling, with services provided to physicians, client laboratories, obstetricians, geneticists, and maternal-fetal medicine specialists primarily in the United States and through international licensing partnerships in Europe and Asia-Pacific. The company operates as a direct wholly owned subsidiary of Laboratory Corporation of America Holdings (LabCorp) following its acquisition in September 2016 for approximately $371 million, which expanded LabCorp's leadership in noninvasive prenatal testing and reproductive genetics while ceasing SQNM's independent Nasdaq trading. Prior to full integration, Sequenom sold its biosciences unit incorporating the MassARRAY system to Agena Bioscience in June 2014 for up to $35.8 million and underwent restructuring in 2017 to prioritize women's health testing, consolidate facilities, and pursue neutral cash flow, alongside efforts to partner for oncology liquid biopsy commercialization.